BACKGROUND: To estimate life years and quality-adjusted life years (QALYs) lost and the economic burden of aneurysmal subarachnoid haemorrhage (aSAH) in the United Kingdom including healthcare and non-healthcare costs from a societal perspective. METHODS: All UK residents in 2005 with aSAH (International Classification of Diseases 10th revision (ICD-10) code I60). Sex and age-specific abridged life tables were generated for a general population and aSAH cohorts. QALYs in each cohort were calculated adjusting the life tables with health-related quality of life (HRQL) data. Healthcare costs included hospital expenditure, cerebrovascular rehabilitation, primary care and community health and social services. Non-healthcare costs included informal care and productivity losses arising from morbidity and premature death. RESULTS: A total of 80,356 life years and 74,807 quality-adjusted life years were estimated to be lost due to aSAH in the UK in 2005. aSAH costs the National Health Service (NHS) pound168.2 million annually with hospital inpatient admissions accounting for 59%, community health and social services for 18%, aSAH-related operations for 15% and cerebrovascular rehabilitation for 6% of the total NHS estimated costs. The average per patient cost for the NHS was estimated to be pound23,294. The total economic burden (including informal care and using the human capital method to estimate production losses) of a SAH in the United Kingdom was estimated to be pound510 million annually. CONCLUSION: The economic and disease burden of aSAH in the United Kingdom is reported in this study. Decision-makers can use these results to complement other information when informing prevention policies in this field and to relate health care expenditures to disease categories.
BACKGROUND: To estimate life years and quality-adjusted life years (QALYs) lost and the economic burden of aneurysmal subarachnoid haemorrhage (aSAH) in the United Kingdom including healthcare and non-healthcare costs from a societal perspective. METHODS: All UK residents in 2005 with aSAH (International Classification of Diseases 10th revision (ICD-10) code I60). Sex and age-specific abridged life tables were generated for a general population and aSAH cohorts. QALYs in each cohort were calculated adjusting the life tables with health-related quality of life (HRQL) data. Healthcare costs included hospital expenditure, cerebrovascular rehabilitation, primary care and community health and social services. Non-healthcare costs included informal care and productivity losses arising from morbidity and premature death. RESULTS: A total of 80,356 life years and 74,807 quality-adjusted life years were estimated to be lost due to aSAH in the UK in 2005. aSAH costs the National Health Service (NHS) pound168.2 million annually with hospital inpatient admissions accounting for 59%, community health and social services for 18%, aSAH-related operations for 15% and cerebrovascular rehabilitation for 6% of the total NHS estimated costs. The average per patient cost for the NHS was estimated to be pound23,294. The total economic burden (including informal care and using the human capital method to estimate production losses) of a SAH in the United Kingdom was estimated to be pound510 million annually. CONCLUSION: The economic and disease burden of aSAH in the United Kingdom is reported in this study. Decision-makers can use these results to complement other information when informing prevention policies in this field and to relate health care expenditures to disease categories.
Authors: P M Rothwell; A J Coull; L E Silver; J F Fairhead; M F Giles; C E Lovelock; J N E Redgrave; L M Bull; S J V Welch; F C Cuthbertson; L E Binney; S A Gutnikov; P Anslow; A P Banning; D Mant; Z Mehta Journal: Lancet Date: 2005-11-19 Impact factor: 79.321
Authors: Andrew J Molyneux; Richard S C Kerr; Ly-Mee Yu; Mike Clarke; Mary Sneade; Julia A Yarnold; Peter Sandercock Journal: Lancet Date: 2005 Sep 3-9 Impact factor: 79.321
Authors: J Ivanidze; R A Charalel; I Shuryak; D Brenner; A Pandya; O N Kallas; K Kesavabhotla; A Z Segal; M S Simon; P C Sanelli Journal: AJNR Am J Neuroradiol Date: 2017-01-12 Impact factor: 3.825
Authors: Felicitas J Detmer; Sara Hadad; Bong Jae Chung; Fernando Mut; Martin Slawski; Norman Juchler; Vartan Kurtcuoglu; Sven Hirsch; Philippe Bijlenga; Yuya Uchiyama; Soichiro Fujimura; Makoto Yamamoto; Yuichi Murayama; Hiroyuki Takao; Timo Koivisto; Juhana Frösen; Juan R Cebral Journal: Neurosurg Focus Date: 2019-07-01 Impact factor: 4.047
Authors: Felicitas J Detmer; Bong Jae Chung; Fernando Mut; Martin Slawski; Farid Hamzei-Sichani; Christopher Putman; Carlos Jiménez; Juan R Cebral Journal: Int J Comput Assist Radiol Surg Date: 2018-08-09 Impact factor: 2.924
Authors: Felicitas J Detmer; Daniel Lückehe; Fernando Mut; Martin Slawski; Sven Hirsch; Philippe Bijlenga; Gabriele von Voigt; Juan R Cebral Journal: Int J Comput Assist Radiol Surg Date: 2019-09-04 Impact factor: 2.924
Authors: Felicitas J Detmer; Bong Jae Chung; Carlos Jimenez; Farid Hamzei-Sichani; David Kallmes; Christopher Putman; Juan R Cebral Journal: Neuroradiology Date: 2018-11-19 Impact factor: 2.804
Authors: Thomas Westermaier; Christian Stetter; Ekkehard Kunze; Nadine Willner; Judith Holzmeier; Judith Weiland; Stefan Koehler; Christopher Lotz; Christian Kilgenstein; Ralf-Ingo Ernestus; Norbert Roewer; Ralf Michael Muellenbach Journal: Neurocrit Care Date: 2016-10 Impact factor: 3.210
Authors: Felicitas J Detmer; Daniel Fajardo-Jiménez; Fernando Mut; Norman Juchler; Sven Hirsch; Vitor Mendes Pereira; Philippe Bijlenga; Juan R Cebral Journal: Acta Neurochir (Wien) Date: 2018-10-30 Impact factor: 2.216